se ha leído el artículo
array:23 [ "pii" => "S0001731012700054" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70005-4" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70005" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:25-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1163 "formatos" => array:2 [ "HTML" => 621 "PDF" => 542 ] ] "itemSiguiente" => array:18 [ "pii" => "S0001731012700066" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70006-6" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70006" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:31-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1299 "formatos" => array:2 [ "HTML" => 740 "PDF" => 559 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab y seguridad cardiovascular" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "31" "paginaFinal" => "38" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab and Cardiovascular Safety" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.C. Ruiz-Carrascosa" "autores" => array:1 [ 0 => array:2 [ "nombre" => "J.C." "apellidos" => "Ruiz-Carrascosa" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700066?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700066/v1_201304241722/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731012700042" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70004-2" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70004" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:16-24" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1703 "formatos" => array:2 [ "HTML" => 1283 "PDF" => 420 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "16" "paginaFinal" => "24" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Jiménez-Puya, J.C. Moreno" "autores" => array:2 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Jiménez-Puya" ] 1 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700042?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Ustekinumab. Análisis de efectos adversos infecciosos" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "25" "paginaFinal" => "30" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "P. Herranz-Pinto, E. Sendagorta" "autores" => array:2 [ 0 => array:4 [ "nombre" => "P." "apellidos" => "Herranz-Pinto" "email" => array:1 [ 0 => "pherranzp@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Sendagorta" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología. Hospital Universitario La Paz. Madrid. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab. Analysis of Rates of Infection" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec85088" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "Efectos adversos" 3 => "Seguridad" 4 => "Infecciones" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec85089" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "Adverse effects" 3 => "Safety" 4 => "Infections" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab es el primer representante de un nuevo grupo de fármacos biológicos, cuyo mecanismo de acción principal es la inhibición selectiva de la actividad de las interleucinas 12 y 23. A pesar de ser la terapia de uso más reciente en dermatología, es el fármaco que mayor número de pacientes ha aportado en su desarrollo clínico en psoriasis. Gracias a esta experiencia acumulada, se ha confirmado que el perfil de seguridad de ustekinumab frente a eventos infecciosos demuestra un riesgo similar a placebo y equiparable a la población general en cuanto a incidencia absoluta, infecciones severas y requerimientos de antibioterapia adicional. Este comportamiento inicial se confirma durante el seguimiento a 3 y 4 años en pacientes con psoriasis moderada a severa.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A pesar de este perfil favorable de seguridad, el carácter inmunosupresor selectivo de ustekinumab aconseja mantener un seguimiento estricto de los pacientes en tratamiento, como el despistaje de infecciones activas o latentes, similar a los aplicados en el caso de los fármacos anti factor de necrosis tumoral.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab is the first of a new class of biologic agents whose main mechanism of action involves the selective inhibition of IL-12 and IL-23. Although ustekinumab is the latest biologic to be approved for use in dermatology, its approval was based on the largest clinical development program conducted to date in psoriasis. Safety data accumulated during the clinical development phase showed the risk of infection to be similar in patients in the ustekinumab and placebo groups. The use of additional antibiotics and the rates of overall infection and serious infection in patients on ustekinumab and the general population were also comparable. Subsequent studies confirmed the safety of this drug in patients with moderate to severe psoriasis treated for 3 or 4 years. Despite its favorable safety profile, ustekinumab is a selective immunosuppressant. Clinicians should therefore closely monitor patients and apply screening measures similar to those used during anti-TNF therapy to detect de novo infections or the reactivation of latent infections.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:16 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F.O. Nestle" 1 => "D.H. Kaplan" 2 => "J. Barker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra0804595" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "361" "paginaInicial" => "496" "paginaFinal" => "509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19641206" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New developments in the treatment of psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Lebwohl" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol." "fecha" => "2002" "volumen" => "138" "paginaInicial" => "686" "paginaFinal" => "688" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12020234" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The IL-23/Th17 axis in the immunopathogenesis of psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Di Cesare" 1 => "P. Di Meglio" 2 => "F.O. Nestle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2009.59" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2009" "volumen" => "129" "paginaInicial" => "1339" "paginaFinal" => "1350" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19322214" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 1 study investigators" "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "A.B. Kimball" 2 => "K.A. Papp" 3 => "N. Yeilding" 4 => "C. Guzzo" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60725-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486739" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 2 study investigators" "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "R.G. Langley" 2 => "M. Lebwohl" 3 => "G.G. Krueger" 4 => "P. Szapary" 5 => "N. Yeilding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60726-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1675" "paginaFinal" => "1684" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486740" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.V. Scanlon" 1 => "B.P. Exter" 2 => "M. Steinberg" 3 => "C.I. Jarvis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1345/aph.1M151" "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "2009" "volumen" => "43" "paginaInicial" => "1456" "paginaFinal" => "1465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19671802" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Leonardi C GL, Wasel N, Yeilding N, Szapary P, Hsu MC, Langley R, et al. Characterization of infections associated with ustekinumab in moderate to severe psoriasis patients. PO49. Psoriasis 2010, Congress of the International Psoriasis Network. Paris, 1–4 Jul 2010." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Gordon K LC, Griffiths CEM, Szapary P, Yeilding N, Hsu MC, Wasel N, et al. Ustekinumab safety update: cumulative experience from longer term follow-up of patients treated in the ustekinumab psoriasis clinical development program. Psoriasis 2010, Congress of the International Psoriasis Network. París, 1–4 Jul 2010. Poster 047." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Reich K LC, Griffiths CEM, Szapary PO, Wasfi Y, Hsu MC, Gordon K on behalf of the PHOENIX 1 & 2 and ACCEPT investigators. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. FC07-03 World Congress of Dermatology. Seúl, Corea, 2011." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G. Trinchieri" 1 => "S. Pflanz" 2 => "R.A. Kastelein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Immunity" "fecha" => "2003" "volumen" => "19" "paginaInicial" => "641" "paginaFinal" => "644" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14614851" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Filipe-Santos" 1 => "J. Bustamante" 2 => "A. Chapgier" 3 => "G. Vogt" 4 => "L. De Beaucoudrey" 5 => "J. Feinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.smim.2006.07.010" "Revista" => array:6 [ "tituloSerie" => "Semin Immunol" "fecha" => "2006" "volumen" => "18" "paginaInicial" => "347" "paginaFinal" => "361" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16997570" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic dissection of immunity to mycobacteria: the human model" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.L. Casanova" 1 => "L. Abel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1146/annurev.immunol.20.081501.125851" "Revista" => array:6 [ "tituloSerie" => "Annu Rev Immunol" "fecha" => "2002" "volumen" => "20" "paginaInicial" => "581" "paginaFinal" => "620" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11861613" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of interleukin-12 in human infectious diseases: only a faint signature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Fieschi" 1 => "J.L. Casanova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/eji.200324038" "Revista" => array:6 [ "tituloSerie" => "Eur J Immunol" "fecha" => "2003" "volumen" => "33" "paginaInicial" => "1461" "paginaFinal" => "1464" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12778462" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. MacLennan" 1 => "C. Fieschi" 2 => "D.A. Lammas" 3 => "C. Picard" 4 => "S.E. Dorman" 5 => "O. Sanal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/425021" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2004" "volumen" => "190" "paginaInicial" => "1755" "paginaFinal" => "1757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15499529" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. De Beaucoudrey" 1 => "A. Samarina" 2 => "J. Bustamante" 3 => "A. Cobat" 4 => "S. Boisson- Dupuis" 5 => "J. Feinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2010" "volumen" => "89" "paginaInicial" => "381" "paginaFinal" => "402" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Herranz-Pinto P S-CE, Casado-Verrier B, Gómez-Fernández C, Alonso-Pacheco ML, Casado-Jiménez ML. Psoriasis en pacientes con coinfección VIH-VHC. Primer año de tratamiento con ustekinumab. Póster Congreso Nacional de Dermatología 2011. Santiago de Compostela, 2011." ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700054?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 5 | 10 | 15 |
2024 Octubre | 31 | 37 | 68 |
2024 Septiembre | 29 | 22 | 51 |
2024 Agosto | 49 | 44 | 93 |
2024 Julio | 41 | 27 | 68 |
2024 Junio | 55 | 28 | 83 |
2024 Mayo | 47 | 45 | 92 |
2024 Abril | 44 | 31 | 75 |
2024 Marzo | 29 | 30 | 59 |
2024 Febrero | 23 | 27 | 50 |
2024 Enero | 18 | 25 | 43 |
2023 Diciembre | 22 | 17 | 39 |
2023 Noviembre | 26 | 21 | 47 |
2023 Octubre | 24 | 18 | 42 |
2023 Septiembre | 22 | 27 | 49 |
2023 Agosto | 26 | 22 | 48 |
2023 Julio | 21 | 26 | 47 |
2023 Junio | 12 | 33 | 45 |
2023 Mayo | 9 | 22 | 31 |
2023 Abril | 17 | 25 | 42 |
2023 Marzo | 15 | 33 | 48 |
2023 Febrero | 17 | 22 | 39 |
2023 Enero | 17 | 31 | 48 |
2022 Diciembre | 22 | 39 | 61 |
2022 Noviembre | 23 | 34 | 57 |
2022 Octubre | 69 | 26 | 95 |
2022 Septiembre | 49 | 40 | 89 |
2022 Agosto | 44 | 45 | 89 |
2022 Julio | 22 | 45 | 67 |
2022 Junio | 15 | 55 | 70 |
2022 Mayo | 22 | 38 | 60 |
2022 Abril | 31 | 30 | 61 |
2022 Marzo | 20 | 42 | 62 |
2022 Febrero | 20 | 26 | 46 |
2022 Enero | 21 | 36 | 57 |
2021 Diciembre | 15 | 32 | 47 |
2021 Noviembre | 22 | 41 | 63 |
2021 Octubre | 21 | 51 | 72 |
2021 Septiembre | 20 | 44 | 64 |
2021 Agosto | 25 | 28 | 53 |
2021 Julio | 11 | 24 | 35 |
2021 Junio | 19 | 49 | 68 |
2021 Mayo | 18 | 40 | 58 |
2021 Abril | 49 | 63 | 112 |
2021 Marzo | 42 | 39 | 81 |
2021 Febrero | 26 | 24 | 50 |
2021 Enero | 25 | 13 | 38 |
2020 Diciembre | 15 | 17 | 32 |
2020 Noviembre | 10 | 17 | 27 |
2020 Octubre | 24 | 12 | 36 |
2020 Septiembre | 11 | 6 | 17 |
2020 Agosto | 21 | 13 | 34 |
2020 Julio | 19 | 11 | 30 |
2020 Junio | 24 | 22 | 46 |
2020 Mayo | 21 | 32 | 53 |
2020 Abril | 20 | 15 | 35 |
2020 Marzo | 25 | 17 | 42 |
2020 Enero | 0 | 5 | 5 |
2019 Diciembre | 0 | 3 | 3 |
2019 Noviembre | 0 | 1 | 1 |
2019 Octubre | 0 | 2 | 2 |
2019 Septiembre | 0 | 5 | 5 |
2019 Agosto | 0 | 1 | 1 |
2019 Julio | 0 | 6 | 6 |
2019 Junio | 0 | 3 | 3 |
2019 Mayo | 0 | 23 | 23 |
2019 Abril | 0 | 25 | 25 |
2019 Febrero | 1 | 5 | 6 |
2019 Enero | 0 | 3 | 3 |
2018 Diciembre | 1 | 7 | 8 |
2018 Noviembre | 0 | 2 | 2 |
2018 Octubre | 0 | 3 | 3 |
2018 Agosto | 0 | 6 | 6 |
2018 Junio | 0 | 4 | 4 |
2018 Febrero | 13 | 5 | 18 |
2018 Enero | 12 | 4 | 16 |
2017 Diciembre | 12 | 9 | 21 |
2017 Noviembre | 10 | 7 | 17 |
2017 Octubre | 8 | 5 | 13 |
2017 Septiembre | 9 | 7 | 16 |
2017 Agosto | 6 | 10 | 16 |
2017 Julio | 12 | 3 | 15 |
2017 Junio | 14 | 6 | 20 |
2017 Mayo | 8 | 9 | 17 |
2017 Abril | 18 | 16 | 34 |
2017 Marzo | 11 | 25 | 36 |
2017 Febrero | 9 | 9 | 18 |
2017 Enero | 10 | 21 | 31 |
2016 Diciembre | 23 | 11 | 34 |
2016 Noviembre | 23 | 12 | 35 |
2016 Octubre | 22 | 9 | 31 |
2016 Septiembre | 30 | 13 | 43 |
2016 Agosto | 29 | 15 | 44 |
2016 Julio | 18 | 8 | 26 |
2016 Junio | 0 | 4 | 4 |
2016 Mayo | 0 | 9 | 9 |
2016 Abril | 1 | 1 | 2 |
2016 Marzo | 0 | 2 | 2 |
2016 Febrero | 0 | 4 | 4 |
2016 Enero | 0 | 16 | 16 |
2015 Diciembre | 0 | 19 | 19 |
2015 Noviembre | 5 | 16 | 21 |
2015 Octubre | 3 | 5 | 8 |
2015 Septiembre | 5 | 13 | 18 |
2015 Agosto | 6 | 7 | 13 |
2015 Julio | 22 | 3 | 25 |
2015 Junio | 21 | 3 | 24 |
2015 Mayo | 45 | 19 | 64 |
2015 Abril | 30 | 12 | 42 |
2015 Marzo | 26 | 20 | 46 |
2015 Febrero | 29 | 10 | 39 |
2015 Enero | 33 | 12 | 45 |
2014 Diciembre | 34 | 8 | 42 |
2014 Noviembre | 23 | 11 | 34 |
2014 Octubre | 34 | 29 | 63 |
2014 Septiembre | 0 | 2 | 2 |
2014 Mayo | 1 | 0 | 1 |
2014 Enero | 0 | 1 | 1 |
2013 Septiembre | 1 | 1 | 2 |
2013 Junio | 0 | 1 | 1 |
2013 Mayo | 1 | 1 | 2 |
2013 Abril | 1 | 2 | 3 |
2013 Febrero | 1 | 2 | 3 |
2013 Enero | 0 | 1 | 1 |